Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open Label, Non-randomized, Multi-Center Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

NCT03925935 is registered in ClinicalTrials.gov with Angiocrine Bioscience as lead sponsor.

NCT NCT03925935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03925935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open Label, Non-randomized, Multi-Center Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation
Lead sponsor
Angiocrine Bioscience
Phase
Phase 1
Overall status
Completed
Start date
May 7, 2019
Completion date
November 8, 2021
Enrollment
42 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma, non-hodgkin lymphoma